ArticlePakistan journal of medical sciences2025
Effect of 0.8mg/ml Losartan on Corneal Opacities.
Article in Pakistan journal of medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Topical losartan to prevent stromal scarring during post-cross-linking infection in pediatric keratoconus: A case report.American journal of ophthalmology case reports · 2026Article
- MCOA: A Comprehensive Multimodal Dataset for Advancing Deep Learning in Corneal Opacity Assessment.Scientific data · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Losartan, commonly used as an angiotensin receptor II inhibitor for hypertension, has recently revealed additional therapeutic properties. Studies demonstrate its potential in treating liver fibrosis, mitigating heart disease secondary to radiation, reducing skin scar formation, and even reversing renal cortical fibrosis. In a specific case, a female patient suffering from persistent bilateral nummular keratitis and corneal opacities experienced significant improvement in her left eye after using 0.8mg/ml Losartan eye drops. Untreated right eye showed no change. Based on the positive outcome, patient was offered same treatment in her right eye as well with monthly follow-ups, which she happily accepted. The stark contrast between the treated and untreated eye highlights the promising role of Losartan in treating corneal opacities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.